toluene-4-sulfonic acid cyclooctylmethyl ester | 16472-97-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: toluene-4-sulfonic acid cyclooctylmethyl ester
• 英文别名: Toluol-4-sulfonsaeure-cyclooctylmethylester；p-Toluolsulfonsaeure-cyclooctylmethylester；Cyclooctylmethyl 4-methylbenzene-1-sulfonate；cyclooctylmethyl 4-methylbenzenesulfonate
• CAS: 16472-97-2
• 化学式: C₁₆H₂₄O₃S
• 分子量: 296.431
• InChiKey: QMVSMWPMVKWHPV-UHFFFAOYSA-N

物化性质

• 沸点：
  425.4±14.0 °C(Predicted)
• 密度：
  1.090±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  51.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  环辛酮 在 palladium on activated charcoal lithium aluminium tetrahydride 、 氢气 、 sodium acetate 、 三乙胺 、 三氯氧磷 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 氯仿 、 水 为溶剂， 20.0 ℃ 、275.8 kPa 条件下， 反应 8.0h， 生成 toluene-4-sulfonic acid cyclooctylmethyl ester
  参考文献：
  名称：

  A New Approach to the Synthesis of the Nonpeptide NOP Receptor Antagonist J-113397

  摘要：

  本研究报道了一种新的合成方法，这种方法无需进行色谱分离即可获得多克量的 J-113397（一种 N/OFQ-NOP 受体系统的竞争性拮抗剂）。以 N-苄基保护的 4-氧代哌啶羧酸酯为起始原料，可获得一种 N-苄基中间体，这种中间体可在合成的相对早期阶段进行分离。合成的关键步骤是还原 1-苄基-4-(3-乙基-2-氧代-2,3-二氢苯并咪唑-1-基)-1,2,5,6-四氢吡啶-3-羧酸甲酯的δ-烯酰胺酯官能团的双键，因为 Pd/C 还原会产生不可分离的混合物。通过在甲醇中使用金属镁处理，可以在一锅反应中将其还原并表聚为所需的反式非对映异构体。

  DOI：

  10.1055/s-2007-966037

文献信息

• [EN] 1-[(INDOL-3-YL)CARBONYL] PIPERAZINE DERIVATIVES<br/>[FR] DERIVES DE 1-[(INDOL-3-YL)CARBONYL] PIPERAZINE
  申请人：AKZO NOBEL NV

  公开号：WO2004000832A1

  公开（公告）日：2003-12-31

  The present invention relates to 1-[(indol-3-yl)carbonyl]piperazine derivative according to the general formula (I), wherein R represents 1-4 substituents independently selected from H, (C1-4)alkyl (optionally substituted with halogen), (C 1-4)alkyloxy (optionally substituted with halogen), halogen, OH, NH2, CN and NO2; R1 is (C5-8)cycloalkyl or (C5-8)cycloalkenyl; R2 is H, methyl or ethyl; R3, R3', R4' R4', R5, R5' and R6' are independently hydrogen or (C1-4)alkyl, optionally substituted with (C1-4)alkyloxy, halogen or OH; R6 is hydrogen or (C1-4)alkyl, optionally substituted with (C1-4)alkyloxy, halogen or OH; or R6 forms together with R7 a 4-7 membered saturated heterocyclic ring, optionally containing a further heteroatom selected from O and S; R7 forms together with R6 a 4-7 membered saturated heterocyclic ring, optionally containing a further heteroatom selected from O and S; or R7 is H, (C1-4)alkyl or (C3-5)cycloalkyl, the alkyl groups being optionally substituted with OH, halogen or (C1-4)alkyloxy; or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising said 1-[(indol-3-yl)carbonyl]piperazine derivatives, and to the use of these derivatives in the treatment of pain, such as peri-operative pain, chronic pain neuropathic pain, cancer pain, and pain and spasticity associated with multiple sclerosis.

  本发明涉及根据通式（I）的1-[(indol-3-yl)carbonyl]哌嗪衍生物，其中R代表独立选择的1-4个取代基，包括H，（C1-4）烷基（可选择用卤素取代），（C1-4）烷氧基（可选择用卤素取代），卤素，羟基，氨基，氰基和硝基；R1为（C5-8）环烷基或（C5-8）环烯基；R2为H，甲基或乙基；R3，R3'，R4'，R4'，R5，R5'和R6'独立地为氢或（C1-4）烷基，可选择用（C1-4）烷氧基，卤素或羟基取代；R6为氢或（C1-4）烷基，可选择用（C1-4）烷氧基，卤素或羟基取代；或R6与R7一起形成一个含有O和S等进一步杂原子的4-7元饱和杂环；R7与R6一起形成一个含有O和S等进一步杂原子的4-7元饱和杂环；或R7为H，（C1-4）烷基或（C3-5）环烷基，烷基基团可选择用羟基，卤素或（C1-4）烷氧基取代；或其药学上可接受的盐。该发明还涉及包含所述1-[(indol-3-yl)carbonyl]哌嗪衍生物的药物组合物，并且涉及在治疗疼痛方面使用这些衍生物，如围手术疼痛，慢性疼痛，神经病性疼痛，癌症疼痛以及与多发性硬化症相关的疼痛和痉挛。
• 1-[(Indol-3-yl)carbonyl]piperazine derivatives
  申请人：Cowley Martin Phillip

  公开号：US20050250760A1

  公开（公告）日：2005-11-10

  The present invention relates to 1-[(indol-3-yl)carbonyl]piperazine derivative according to the general formula I or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising said 1-[(indol-3-yl)carbonyl]piperazine derivatives, and to the use of these derivatives in the treatment of pain, such as peri-operative pain, chronic pain neuropathic pain, cancer pain, and pain and spasticity associated with multiple sclerosis.

  本发明涉及一种符合通式I的1-[(indol-3-yl)carbonyl]piperazine衍生物，或其药学上可接受的盐。本发明还涉及包含上述1-[(indol-3-yl)carbonyl]piperazine衍生物的药物组合物，以及利用这些衍生物治疗疼痛，例如围手术期疼痛、慢性疼痛、神经病理性疼痛、癌症疼痛以及与多发性硬化相关的疼痛和痉挛。
• Piperidin-4-yl urea derivatives and related compounds as chemokine receptor inhibitors for the treatment of inflammatory diseases
  申请人：Watson John Robert

  公开号：US20050113414A1

  公开（公告）日：2005-05-26

  Cyclic amino derivatives of formula (1) are described: (1) wherein: m and n, which may be the same or different, is each zero or the integer 1 or 2; Alk 3 is a covalent bond or a straight or branched C 1-6 alkylene chain; R 1 and R 2 , which may be the same or different, is each a hydrogen atom or a straight or branched C 1-6 alkyl group; D is an optionally substituted aromatic or heteroaromatic group; E is an optionally substituted C 7-10 cycloalkyl, C 7-10 cycloalkenyl or C 7-10 polycycloaliphatic group; and the salts, solvates, hydrates, tautomers or N-oxides thereof. The compounds are potent and selective modulators of the interaction between CXCR3 and its chemokine ligands and are thus of use in medicine, for example in the prevention or treatment of conditions involving inappropriate T-cell trafficking such as certain inflammatory, autoimmune and immunoregulatory disorders as described hereinafter.

  描述了公式（1）的环状氨衍生物：（1）其中：m和n，可以相同或不同，均为零或整数1或2; Alk3是共价键或直链或支链C1-6烷基链; R1和R2，可以相同或不同，均为氢原子或直链或支链C1-6烷基基团; D是可选的取代芳香族或杂环芳香族基团; E是可选的取代C7-10环烷基，C7-10环烯基或C7-10多环脂肪族基团;以及其盐，溶剂化物，水合物，互变异构体或N-氧化物。这些化合物是CXCR3与其趋化因子配体之间相互作用的强效和选择性调节剂，因此在医学上有用，例如在预防或治疗涉及不适当T细胞转移的疾病中，如下所述的某些炎症，自身免疫和免疫调节性疾病。
• 1- (INDOL-3-YL)CARBONYL PIPERAZINE DERIVATIVES
  申请人：N.V. Organon

  公开号：EP1549637B1

  公开（公告）日：2007-05-02
• US7304064B2
  申请人：——

  公开号：US7304064B2

  公开（公告）日：2007-12-04